The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer’s Disease
Open accessAbstract
Markers of Alzheimer's disease (AD) are being widely sought with a number of studies suggesting blood measures of inflammatory proteins as putative biomarkers. Here we report findings from a panel of 27 cytokines and related proteins in over 350 subjects with AD, subjects with Mild Cognitive Impairment (MCI) and elderly normal controls where we also have measures of longitudinal change in cognition and baseline neuroimaging measures of atrophy. In this study, we identify five inflammatory proteins associated with evidence of atrophy on MR imaging data particularly in whole brain, ventricular and entorhinal cortex measures. In addition, we observed six analytes that showed significant change (over a period of one year) in people with fast cognitive decline compared to those with intermediate and slow decline. One of these (IL-10) was also associated with brain atrophy in AD. In conclusion, IL-10 was associated with both clinical and imaging evidence of severity of disease and might therefore have potential to act as biomarker of disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While pathways involving mitochondrial dysfunction or inflammation have been linked to rapid progression, these proteomic and physiological associations may be downstream effects of true drivers of progression [9–11].”
From Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk (2026) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Elevated CCL11 in the plasma and cerebrospinal fluid seen in aging mice and humans are associated with declining neurogenesis, neurodegenerative disease, and cognitive decline and may contribute to driving neovascularisation in AMD via interaction with CCR3 [1, 93, 123].”
From Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain (2022) · cites this paper as [93]
In the citing paper
“Elevated CCL11 in the plasma and cerebrospinal fluid seen in aging mice and humans are associated with declining neurogenesis, neurodegenerative disease, and cognitive decline and may contribute to driving neovascularisation in AMD via interaction with CCR3 [1, 93, 123].”
From Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain (2022) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“McGeer & Zhao showed IL-10 can be produced by microglia [35,36].”
BackgroundClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Cytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
Frei, K., Malipiero, U., Leist, T. P., Zinkernagel, R. M., Schwab, M. E., & Fontana, A. (1989) · European Journal of Immunology · doi:10.1002/eji.1830190418 · Cited by 690
Perry, V. H. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.01.004 · Cited by 560
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Petrella, J. R., Coleman, R. E., & Doraiswamy, P. M. (2003) · Radiology · doi:10.1148/radiol.2262011600 · Cited by 427
Flagged first, then by citations
Research works printed but not linked: 1
- Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, <etal>et al</etal>.. (2012) Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol: 1–8. · DOI · Paper page
Cited by
Sorted by citations
Items 101–161 of 161
Ojo, J. O., Crynen, G. C., Reed, J. M., Ajoy, R., Vallabhaneni, P., Algamal, M., Leary, P., Rafi, N. G., Mouzon, B., MULLAN, M. J., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00405 · Cited by 13
Wang, W., Lu, L., Wu, Q., & Jia, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160004 · Cited by 12
Rochette, L., Méloux, A., Rigal, E., Zeller, M., Cottin, Y., Malka, G., & Vergely, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123998 · Cited by 14
Hernandez, C. M., McCuiston, M. A., Davis, K., Halls, Y., Zotto, J. P. C. D., Jackson, N. L., Dobrunz, L. E., King, P. H., & McMahon, L. L. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100798 · Cited by 11
CCL11 (Eotaxin) Promotes the Advancement of Aging-Related Cardiovascular Diseases
Zhang, T., Huang, Y., Ji, X., Wu, T., & Xiao, P. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26020 · Cited by 10
Mahdavi, M., Karima, S., Rajaei, S., Aghamolaii, V., Ghahremani, H., Ataeia, R., Tehrani, H. S., Baram, S. M., Tafakhori, A., Lima, B. S., et al. (2021) · Galen Medical Journal · doi:10.31661/gmj.v10i0.1974 · Cited by 10
Huo, C., Chen, M., Hour, T., Huang, L., Fong, Y.-O., Kuo, Y., Yang, Y., & Chuu, C. (2022) · Brain Sciences · doi:10.3390/brainsci12091134 · Cited by 8
Julian, A., Bilan, A. R., Ragot, S., Krolak‐Salmon, P., Berrut, G., DANTOINE, T. F., Hommet, C., Hanon, O., Page, G., & Paccalin, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171131 · Cited by 8
Afrakoti, L. G. M. P., Moghadam, S. D., & Hadinezhad, P. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251329188 · Cited by 12
Fierro-Salgado, Y. T., Reiriz, M., Beltrán-Velasco, A. I., Calleja-Conde, J., Hernández-Oñativia, X., Uceda, S., & Echeverry-Alzate, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010074 · Cited by 7
Biomarkers of chronic traumatic encephalopathy: A state-of-the art review
Gerges, J. A., Chalhoub, I., Atallah, C., & Khoury, R. (2023) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2023.100066 · Cited by 7
Carvalho, D. B., Díaz‐Amarilla, P., Dapueto, R., Santi, M. D., Duarte, P., Savio, E., Engler, H., Abin‐Carriquiry, J. A., & Arredondo, F. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02105-2 · Cited by 7
Rudisch, D. M., Krasko, M. N., Barnett, D. G. S., Mueller, K. D., Russell, J. A., Connor, N. P., & Ciucci, M. R. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1294648 · Cited by 7
Khatri, A., Prakash, O., Agarwal, R., & Kushwaha, S. S. (2024) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_975_23 · Cited by 6
Ho, G. J., Lam, L. Q., Tran, T. T., Wei, J., & Hashimoto, M. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1430593 · Cited by 7
Antequera, D., Carrero, L., Alves, V. C., Ferrer, I., Hernández‐Gallego, J., Municio, C., & Carro, E. (2022) · Biomedicines · doi:10.3390/biomedicines10071645 · Cited by 6
Nakamichi, A., Kimura, N., Hanaoka, T., Masuda, T., Ataka, T., & Matsubara, E. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251315181 · Cited by 5
Comparison of Inflammatory Markers as Moderators of Depression Outcomes: A CO-MED Study
Czysz, A. H., Mason, B. L., Li, Q., Chin-Fatt, C., Minhajuddin, A., Carmody, T., & Trivedi, M. H. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.116 · Cited by 4
Pyo, J. H., Han, S. S., Kim, M.-J., Moon, Y. K., Lee, S. J., Lee, C., Lee, A., Lim, S., & Kim, D. K. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100356 · Cited by 4
Mathew, J., Maroky, A. S., SINDURAJ, S., & Chandrababu, A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i5.54564 · Cited by 3
Plasma Cytokine Biomarker Cutoff Values for HIV-Associated Neurocognitive Impairment in Adults
Ruhanya, V., Jacobs, G. B., Paul, R. H., Joska, J. A., Seedat, S., Nyandoro, G., Engelbrecht, S., & Glashoff, R. H. (2021) · Viral Immunology · doi:10.1089/vim.2021.0047 · Cited by 3
van Setten, A., Uleman, J. F., Melis, R. J. F., LAWLOR, B. A., Riksen, N. P., Claassen, J. A. H. R., de Heus, R. A. A., on behalf of NILVAD Study Group, Segurado, R., Kennelly, S., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01294-x · Cited by 3
Self-citationBiochemical and Radiological Markers of Alzheimer’s Disease Progression
Dziedzic, T., Pera, J., Klimkowicz‐Mrowiec, A., Mroczko, B., & Słowik, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/ifs-150578 · Cited by 3
Wu, Y., Srirajavatsavai, V., Monplaisir, K. M., Sambanthamurthi, R., & Gupta, S. V. (2015) · The FASEB Journal · doi:10.1096/fasebj.29.1_supplement.271.8 · Cited by 3
Plasma IL-6 Levels as a Biomarker for Behavioral Changes in Alzheimer’s Disease
Yasuno, F., Watanabe, A., Kimura, Y., Yamauchi, Y., Ogata, A., Ikenuma, H., Abe, J., Minami, H., Nihashi, T., Yokoi, K., et al. (2025) · NeuroImmunoModulation · doi:10.1159/000547726 · Cited by 2
Saeedi, F. H., Shahsavarani, H., Hosseini, S., Farrokhi, N., Ghosal, K., Thomas, S., Alipour, A., Ingvarsson, P. K., & Jahanfar, M. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1766388 · Cited by 2
Development of early biomarkers of Alzheimer's disease: A precision medicine perspective
Sarkar, S., Das, N., & Sambamurti, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00006-x · Cited by 2
Mitochondrial Dysfunction and Its Role in Neurological Disorders
Rather, G. A., Mathur, V., Riyaz, M., Yadav, R., Nanda, A., Siddiqui, A. J., Rather, M. A., Khan, A., & Jahan, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-9404-5_13 · Cited by 2
Tan, M. S., Cheah, P., Chin, A., Looi, L., & Chang, S. (2024) · PeerJ · doi:10.7717/peerj.17643 · Cited by 2
Morrison, L., Dyer, A. H., Dolphin, H., Batten, I., Reddy, C., Widdowson, M., Woods, C. P., Gibney, J., Bourke, N. M., & Kennelly, S. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100862 · Cited by 2
Yeram, N., Dalvi, S. M., Kale, V. P., Patil, V. W., Mankeshwar, R., Jagiasi, K., & Abichandani, L. G. (2025) · Neurology India · doi:10.4103/neuroindia.ni_1615_20 · Cited by 2
The Effect of Nutrients on Alzheimer’s Disease Biomarkers: A Metabolomic Approach
Kalli, Ε. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-78787-5_35 · Cited by 2
Current and Developing Methods for Diagnosing Alzheimer's Disease
Fuller, S. J., Carrigan, N., Sohrabi, H. R., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch3 · Cited by 2
Genetic drivers of progression in Alzheimer’s disease are distinct from disease risk
Cohen, C. E., Fernandez, S., Yaman, U., Ehyaei, A. R., Kodosaki, E., Askarova, A., Porter, T., O’Brien, E., Study, A. I. B. A. L., Initiative, A. D. N., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02036-1 · Cited by 1
Karima, S., Mahdavi, M., Rajaei, S., Lima, B. S., Ataeia, R., Tehrani, H. S., Baram, S. M., Tafakhori, A., Shateri, S., Fatemi, H., et al. (2021) · Galen Medical Journal · doi:10.31661/gmj.v10i.1974 · Cited by 1
Cognitive impairment in neuromyelitis optica spectrum disorders
Алексеевна, В. Е., Kasatkin, D. S., Korchevnyi, S. E., & Bereznyak, K. I. (2024) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2024-3-117-122 · Cited by 1
Cynthia, C., Nugraha, J., Hamdan, M., Notobroto, H. B., Lumempouw, S. F., & Dharma, R. S. (2024) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v16i6.3404 · Cited by 1
Price, R., Moreno, M. R., Cooper, A. S., Singh, R., Khaw, Y. M., Mhaka, A. M., Sivanantharajah, L., & Mudher, A. K. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2498675 · Cited by 1
Azmoun, S., Lewis, F. C., Shoieb, D., Jin, Y., Colicino, E., Mhatre‐Winters, I., Gu, H., Krishnamurthy, H. K., Richardson, J. R., Placidi, D., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15080829 · Cited by 1
Systemic infections alter cortical transcriptional signatures in Alzheimer’s disease
Pegoraro, G., MacBean, L. F., Smith, A. R., Soanes, D. M., Smith, R. G., Imm, J. L., Harvey, J., Kouhsar, M. P., Laroche, V., Weymouth, L. S., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.06.010 · Cited by 1
Self-citationIs Detection of Preclinical Alzheimer’s Disease Possible?
Brawer, S. (2018) · Touro Scholar (Touro College) · Cited by 1
Gawryś, A., Cholewa, M. M., Kromer, A., Wilk, J., Cichoń, K., Zapała, M. A., Łapaj, M., Chyćko, M., Środoń, A., & CZARNOTA, J. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.46.01.015 · Cited by 1
Systemic inflammation causes microglial dysfunction with a mixed AD-like pathologyPreprint
Bathini, P., Dupanloup, I., Zenaro, E., Terrabuio, E., Fischer, A., Ballabani, E., Doucey, M., & Alberi, L. A. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.27.223198 · Cited by 1
Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Bubu, O. M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4076789/v1 · Cited by 1
Sistema melatonérgico como alvo do peptídeo β-amiloide
Cecon, E. (2014) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2014.tde-29092014-083625
Sarlus, H. (2015) · Figshare
NT-pro BNP as a Blood Biomark- er for Alzheimer's Disease
Ws, B., & Bernardino, S. (2014)
Nevado-Holgado, A., Ribe, E. M., Thei, L., Furlong, L., Angel-Mayer, M., Quan, J., Richardson, J., Cavanagh, J., & Lovestone, S. (2017) · bioRxiv · doi:10.1101/179267 · Cited by 1
Self-citationSystemic Inflammation Causes Microglial Dysfunction with a Mixed AD-Like Pathology.Preprint
Bathini, P., Dupanloup, I., Zenaro, E., Terrabuio, E., Fisher, A., Babaliani, E., Doucey, M., & Alberi, L. A. (2020) · Research Square · doi:10.21203/rs.3.rs-48807/v1
Insilico Identification of Genes and Molecular Pathways during Aging in Drosophila Brain
Parakh, A., Begde, D. N., Dhingra, N., & Sinha, D. (2021) · Advances in Aging Research · doi:10.4236/aar.2021.104005
Colloidal SERS sensors for inflammatory biomarker detection in urine for patient risk stratificationPreprint
Kidd, R., Anderson, W., Prince, J. P., Agyemang-Prempeh, A., Roach, P. L., Newman, T. A., & Mahajan, S. (2021) · doi:10.33774/chemrxiv-2021-bsx14
Colloidal SERS sensors for inflammatory biomarker detection in urine for patient risk stratificationPreprint
Kidd, R., Anderson, W., Prince, J. P., Agyemang-Prempeh, A., Roach, P. L., Newman, T. A., & Mahajan, S. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-bsx14
Longitudinal associations between serum cytokine levels and dementia
Kim, J., & JinSang, Y. (2018) · doi:10.26226/morressier.5b681763b56e9b005965bfd5
Nielsen, J. E. (2021) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau455017331
Azmoun, S., Lewis, F., Shoieb, D., Jin, Y., Colicino, E., Mhatre‐Winters, I., Gu, H., Krishnamurthy, H. K., Richardson, J. R., Placidi, D., et al. (2025) · medRxiv · doi:10.1101/2025.05.02.25326824
Toniolo, S., Zhao, S., Broulidakis, M. J., Gendarini, C., Sinha, D., Tahira, N., Scholcz, A., Amein, B., Fower, A., van Duijn, C. M., et al. (2025) · medRxiv · doi:10.1101/2025.11.13.25340143
Jacobs, T., Jacobson, S. R., Fortea, J., Berger, J. S., Vedvyas, A., Marsh, K., He, T., Gutiérrez‐Jiménez, E., Fillmore, N. R., Gonzalez, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25853015
Mobilisation de l'acide arachidonique et sensibilité au peptide ß-amyloïde
Thomas, M. H. (2015) · theses.fr (ABES) · doi:10.70675/904987d5zc8c8z4104z95dfz2f7e680d8be3
Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer
Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261
Coury, S. M., Lopez, S. D., Savoca, P. W., Gaines, E. M., Parenti, B., Razon, A., Dosanjh, K. K., Labus, J. S., Jacobs, J. P., Eich, T. S., et al. (2026) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2026.101294
Mitchell, B. A., Hausle, I., Smith, S., Thropp, P., Sirota, M., Tosun, D., & Initiative, A. D. N. (2026) · npj Dementia · doi:10.1038/s44400-026-00100-z
Metadata
- Authors
- Leung, R., Proitsi, P., Simmons, A., Lunnon, K., Güntert, A., Kronenberg, D., Pritchard, M., Tsolaki, M., Mecocci, P., Kloszewska, I., Vellas, B., Soininen, H., Wahlund, L.-O., & Lovestone, S.
- Affiliations
- King's College London (GB)
- Aristotle University of Thessaloniki (GR)
- University of Perugia (IT)
- Inserm (FR)
- University of Eastern Finland (FI)
- Corresponding author
- Lovestone, Simon
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-10
- Volume
- 8
- Issue
- 6
- Pages
- e64971
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3677891
- OpenAlex
- W2086474013
- Cited by
- 160
- References
- 43
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 18 · 2023: 12 · 2022: 13 · 2021: 19 · 2020: 13 · 2019: 9 · 2018: 15 · 2017: 10 · 2016: 6 · 2015: 15 · 2014: 9 · 2013: 2
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open Research Exeter (University of Exeter) (publishedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- Wellcome Trust (100140)
- National Institute for Health and Care Research (NF-SI-0512-10053)
- King's College London
- European Commission (FP6-2004-LIFESCIHEALTH-5)
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, inflammatory proteins, cytokines, biomarkers, disease severity, mild cognitive impairment, brain atrophy, entorhinal cortex, ventriculomegaly, IL-10, cognitive decline, disease progression, neuroimaging
- MeSH terms
- Aged, Alzheimer Disease, Atrophy, Brain, Cognition Disorders, Enzyme-Linked Immunosorbent Assay, Female, Humans, Magnetic Resonance Imaging, Male, Prognosis, Severity of Illness Index, Cohort Studies, Biomarkers, Case-Control Studies, Cytokines, Disease Progression, Inflammation Mediators, Functional Neuroimaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
